Commonwealth announced the launch of IBSchek, a blood test to guide physicians in the diagnosis of irritable bowel syndrome (IBS).
The IBSchek works by identifying the presence of anti-CdtB and anti-vinculin in the blood sample, which are two antibodies that have been shown to indicate diarrhea-predominant IBS. It is an enzyme-linked immunosorbent assay (ELISA) based test that provides a result within 24 hours of the patient’s blood sample. The test was evaluated in a large-scale, multi-center, randomized clinical trial of 2,681 patients with IBS, inflammatory bowel disease (IBD), celiac disease, or healthy controls and the results were published in PLOS ONE.
A positive result on the IBSchek may indicate there is a high degree of medical certainty that the patient has diarrhea-predominant IBS and not IBD or celiac disease. An inconclusive IBSchek may mean that further investigation into the cause of symptoms may be needed, the cause of IBS may be due to an alternate mechanism outside of the scope of IBSchek, or that the symptoms maybe caused by a disease other than IBS.
Researchers concluded that IBSchek is an important tool that can help clinicians quickly and accurately diagnose IBS.
For more information call (877) 427-2435 or visit IBSchek.com.